Entyvio (vedolizumab) blocks a protein on the surface of white blood cells that get into the gut and cause inflammation in ulcerative colitis and Crohn’s disease. By doing this, the amount of inflammation is reduced.1
Entyvio is used to treat the signs and symptoms of:1
Ulcerative Colitis (UC) – Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.
Crohn’s Disease (CD) – Adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.LEARN MORE
It is important that you read the Patient Information Leaflet that came with your medicine and keep a copy for future reference.
In addition, you should have been given a Patient Alert Card which contains important safety information and should be shown to any healthcare professional involved in your treatment.
Download the Entyvio Patient Information Leaflet
DOWNLOAD THE ENTYVIO PATIENT ALERT CARD
Entyvio reduces inflammation in the gastrointestinal tract of adults with moderately to severely active UC and CD.1
Entyvio is currently available in two forms – one form (subcutaneous) is injected just below the skin, the other form (intravenous) is put directly into a vein.LEARN MORE ABOUT HOW YOUR MEDICATION IS GIVEN
Reporting of Side Effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed on this website or in the Patient Information Leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.